The strongest single argument for follow-up: people whose gut hasn't actually healed carry roughly three times the lymphoma risk of people who did (Lebwohl et al. 2013), and the only way to tell who's in which group is to look. The rest of the protocol — a yearly antibody draw, a nutrient panel, a bone-density scan, a dietitian relationship in year one — exists because feeling fine and being fine are not the same thing in celiac, and because each of your first-degree relatives is sitting on a one-in-ten chance of carrying the disease themselves (Singh et al. 2015). None of it is daily work. Most of it is a single morning a year.
The disconnect to internalise is between three things that drift apart in celiac and are easy to confuse: how you feel, what your antibodies say, and what your gut actually looks like. Symptoms clear first — most people on a strict gluten-free diet feel substantially better within months. Antibody titres (the tTG-IgA blood test) fall next, usually over six to twelve months (Husby et al. 2019). The villi themselves — the absorptive fingers lining the small intestine — heal last, and in a lot of adults they never fully heal. About a third of adults are healed at two years, two-thirds by five years; the rest live with ongoing damage on a diet they believe is strict (Rubio-Tapia et al. 2010).
That gap is the whole reason a follow-up protocol exists. The bloodwork is not just a check on whether you're eating gluten on purpose — it's a check on whether your body is still being injured by gluten you didn't know was there. Restaurant kitchens, shared toasters, soy sauce, malt vinegar, the seasoning on a bag of crisps. Patient registries report that roughly three in four celiacs were accidentally exposed in the last month. Yearly labs and an honest dietitian visit are the system that catches the slow drift.
Why the gut-healing question is worth asking
The reason this isn't paranoid medicine: there's a real difference in long-term outcome between the celiacs whose gut heals on the diet and the ones whose doesn't. The Swedish population cohort with paired biopsies — about 7,600 patients — is the cleanest read on what's at stake.
The cancer at issue — enteropathy-associated T-cell lymphoma — is rare in absolute terms, but it's deadly when it happens and concentrated in exactly the people whose villi never healed. The relevant comparison isn't healthy people; it's two versions of you, one whose intestine recovered and one whose didn't. The version whose gut quietly stays inflamed is the one carrying the risk.
The same gut damage drives the second-order effects readers feel more directly. About one in three newly-diagnosed adults has iron-deficiency anemia, four in five have at least one micronutrient running low, and the most common deficiency at diagnosis is zinc — present in roughly 59% of patients (Bledsoe et al. 2019) (Wierdsma et al. 2013). None of that resolves on its own from a gluten-free diet alone; the damaged gut absorbs them poorly even after the trigger is gone, and most gluten-free foods aren't fortified the way wheat-based foods are. Without the yearly labs and the targeted supplementation that follows, these run for years.
And then there's the bone story. Roughly a third of adults have osteopenia and another third have osteoporosis at the time of celiac diagnosis — most without ever having broken a bone or thought about it. Celiac roughly doubles fracture risk in case-control studies, and lifts hip-fracture risk by about 70% in long-term follow-up (Heikkilä et al. 2015) (Olmos et al. 2008). The baseline DXA is what tells you whether you're walking around with hidden bone loss; without it, the first time you find out is when something breaks.
What to actually do, year by year
The American College of Gastroenterology's 2023 update is the most recent explicit playbook for adults (Rubio-Tapia et al. 2023), with the British and European guidelines tracking it closely (Ludvigsson et al. 2014). The pieces below are the converged core; the disputed pieces are flagged.
The first year
Three to four clinic visits, typically at three, six, and twelve months. A dietitian appointment is not optional — it's the single highest-yield intervention in year one and most guidelines treat it as mandatory (Rubio-Tapia et al. 2023). Without it, the rate of inadvertent gluten exposure stays high and so does the rate of persistent villous damage.
Repeat tTG-IgA at six months and twelve months — falling titres confirm the diet is working; rising or stuck-positive titres mean gluten is getting through somewhere and the dietitian visit needs to happen again (Husby et al. 2019). Recheck any deficient nutrients at three to six months.
Every year after that
The bone scan
The American guideline says a DXA at diagnosis for adults and another every two to three years (Rubio-Tapia et al. 2023). The British and European guidelines limit repeat scans to people who had abnormal baseline results, or to adults over 55 with extra risk factors (Ludvigsson et al. 2014). The reasonable middle path: get the baseline scan; if it's normal and you have no other risk factors, you can stretch the next one out to five years. If it shows osteopenia or osteoporosis, you need a treatment plan and earlier recheck.
The follow-up biopsy
This is the contested one. A repeat upper-endoscopy biopsy at the two-year mark is the only direct way to confirm the gut has healed. The case for doing it: persistent villous damage is the single best marker of long-term lymphoma risk and a substantial fraction of patients with normal antibodies still have ongoing damage (Lebwohl et al. 2013). The case against: it's an invasive procedure with sedation, the same Swedish cohort found no all-cause mortality difference between healed and not-healed groups (Lebwohl et al. 2013), and there's no trial proving the biopsy result changes patient-level decisions. The American guideline now phrases it as "consider after shared decision-making at two years" (Rubio-Tapia et al. 2023). In symptomatic patients, or anyone whose antibodies haven't come down, the biopsy is no longer optional — it's how refractory celiac gets diagnosed.
Your family is also part of this
This is the piece that gets dropped the most often and matters the most per dollar spent. Every parent, full sibling, and biological child of yours has roughly a one-in-ten chance of also carrying celiac disease — about a sevenfold rise over the general population's one-in-a-hundred, with sisters and daughters carrying the highest risk (Singh et al. 2015). Most of them don't know it. Up to six in ten relatives who screen positive call themselves asymptomatic until you ask them in detail, and then it turns out the chronic fatigue, the iron-deficiency anemia, the brain fog, the chronic diarrhoea a doctor once waved off as IBS — all of it they'd attributed to getting older or being stressed — has been the disease all along.
One option worth knowing about: a one-time HLA-DQ2/DQ8 gene test (a cheek swab) can essentially rule out future risk in a relative who's gene-negative. About 30-40% of the population carries one of these alleles; if the test comes back clean, that relative is statistically very unlikely to ever develop celiac and doesn't need repeated screening. If the gene test is positive, it doesn't mean they have the disease — only that they could develop it — and the tTG follow-up continues.
Where this falls apart
- Dropping out after year one. The most common failure. Patient feels well, dietitian visits stop, antibody draws lapse, the family never gets tested. The slow drift of inadvertent gluten exposure stops being caught. Refractory celiac — the 1-2% of patients who don't heal despite genuine adherence — goes undiagnosed for years.
- Trusting the antibody by itself. The tTG-IgA is roughly 50% sensitive for persistent gut damage (Husby et al. 2019). If symptoms have not resolved, or have come back, the next step is endoscopy and biopsy — not reassurance that the bloodwork is fine.
- Missing IgA deficiency at baseline. About 2-3% of celiacs are selectively IgA-deficient, and in those patients the tTG-IgA reads falsely negative forever. Total IgA on the first draw catches this; switch to IgG-based antibodies if it's low (Husby et al. 2019).
- Relatives going gluten-free before being tested. The most common screening failure. Once someone has been off gluten for weeks, the antibody normalises and the biopsy improves — the workup becomes uninformative. Eat gluten until tested.
- Quiet cross-contamination drift. A year of restaurant meals, shared kitchen tools, and "this should be safe" can re-establish low-grade exposure without the patient noticing. A yearly dietitian visit catches what self-monitoring misses.
- Not actually replacing what's low. A nutrient panel that shows a deficiency only helps if the supplementation happens. Iron, vitamin D, B12, and zinc replacement need to be tracked to the point of normal levels, then maintained.
What changes when you stay on it
Within six months, the antibody titres are falling and the dietitian has caught the things you didn't realise were gluten — the soy sauce, the malt-flavoured cereal, the shared toaster, the seasoning on a snack. The fatigue floor that the gluten-free diet alone couldn't lift comes off once iron and B12 are replaced; people around you stop commenting that you look tired.
By the end of year one, the bone scan has either given you a clean baseline you'll keep or flagged osteopenia early enough to do something about — calcium, vitamin D, weight-bearing exercise, and where indicated, anti-osteoporotic medication. Either way, the surprise hip fracture in your sixties becomes less likely.
By year two, the second antibody trend confirms the diet is holding, and the call on whether to repeat the biopsy is no longer abstract: you have a real conversation about whether your symptoms and antibodies are consistent enough with healed villi to skip it. Patients who do heal histologically have lymphoma risk that sits roughly at the general-population baseline (Lebwohl et al. 2013) — the surveillance has paid its way.
The bigger compound effect is at the family level. The sister who'd been chronically iron-deficient gets diagnosed at 38 instead of 53, the brother whose anxiety turned out to be undiagnosed celiac goes through a different decade, the kid who would have grown poorly catches it before puberty. A 7.5% chance per relative, plus three or four relatives — the math says someone in your family is going to test positive, and finding them early is most of the lasting value of the whole exercise (Singh et al. 2015).
Related rabbit holes
- The gluten-free diet itself — what counts as gluten, cross-contamination habits, label-reading, eating out — is its own large topic and the dietitian visits are the place to learn it.
- Refractory celiac disease — the rare 1-2% who don't heal on strict adherence — needs specialist care beyond standard follow-up.
- Non-celiac gluten sensitivity is a different condition with overlapping symptoms but no autoimmune component or family-screening implications.
- Other autoimmune conditions overrepresented in celiac patients — type 1 diabetes, autoimmune thyroid, dermatitis herpetiformis — are worth knowing about and worth periodic screening for, separate from this entry.
- Bone-density treatment (calcium, vitamin D dosing, bisphosphonates) sits adjacent to the DXA result but is its own decision.
- — Chronic diarrhoea written off as IBS is a common way undiagnosed celiac hides; testing settles it.
- — If your celiac diagnosis was never nailed down, this gene test can rule it out for good — no going back on gluten.
- — A damaged gut leaves nutrient gaps — iron is the classic one, which is why follow-up labs check ferritin.
- — Anyone who reacts to wheat needs celiac excluded before self-diagnosing a milder sensitivity; the test only works on a gluten-containing diet.
- — Celiac quietly thins bone before diagnosis — the bone-density scan is part of follow-up for a reason.
- — A damaged gut absorbs fat-soluble vitamins poorly, so low vitamin D is common, and it feeds the bone loss the scan checks for.
- — Celiac travels with other autoimmune diseases, thyroid especially. Part of follow-up is staying alert for the next one.
- — Celiac travels with type 1 diabetes — same autoimmune genes. If T1D runs in the family too, ask about screening relatives.
Substance + claimed effects
Celiac follow-up is the post-diagnosis monitoring stack: serology (tTG-IgA) at intervals to confirm dietary adherence, micronutrient labs to catch deficiencies the damaged villi created, a baseline bone-density (DXA) scan to detect the osteopenia/osteoporosis present in roughly a third of adults at diagnosis, a follow-up duodenal biopsy at 1-2 years to confirm mucosal healing, and active case-finding in first-degree relatives (FDRs). The claimed consequences this entry covers: reduced risk of enteropathy-associated T-cell lymphoma and other lymphoproliferative malignancies via mucosal healing surveillance; correction of iron, B12, folate, vitamin D, zinc, and copper deficiencies that drive anemia, fatigue, and neurological symptoms; prevention of fragility fractures via DXA-guided bone treatment; and detection of the 7-8% of FDRs who carry the disease and don't know it (Singh et al. 2015).
Evidence by addressing question
mechanism
Celiac disease is a gluten-driven autoimmune enteropathy that destroys small-bowel villi in genetically predisposed people (HLA-DQ2 in ~90%, HLA-DQ8 in most of the rest) (Ludvigsson et al. 2014). A strict gluten-free diet (GFD) removes the trigger, allowing villi to regrow over months to years, but the recovery is incomplete in a substantial minority — and that incompleteness is what the follow-up stack is designed to detect.
Each piece of the stack maps to a different failure mode of GFD treatment:
- tTG-IgA serology tracks the autoantibody titre — it falls within 6-12 months on a gluten-free diet and rising or persistently positive levels usually mean ongoing gluten exposure. The AGA notes its sensitivity for histologic recovery is only ~50% (specificity ~83%), so normal serology does not prove healed mucosa — the patient can still have villous atrophy with negative serology (Husby et al. 2019).
- Follow-up duodenal biopsy is the only direct read on mucosal healing. Even with good adherence, only ~35% recover histologically by 2 years and ~66% by 5 years; the rest live with persistent villous atrophy on a GFD they believe is strict (Rubio-Tapia et al. 2010).
- Micronutrient labs reflect the iron/B12/folate/vitamin-D/zinc/copper deficiencies that the duodenum couldn't absorb before diagnosis and may continue to under-absorb until villi recover. Zinc deficiency at diagnosis is the most common (~59% in the Mayo cohort) (Bledsoe et al. 2019); iron and vitamin D are close behind.
- DXA detects the bone loss that secondary hyperparathyroidism (from calcium/vitamin-D malabsorption) and inflammation drove during the untreated years. ~30-40% of newly diagnosed adults have osteopenia or osteoporosis even without classic symptoms.
- FDR screening rests on heritability — celiac is one of the most heritable autoimmune diseases, with HLA-DQ2/DQ8 plus shared environmental gluten exposure giving siblings, parents, and children a roughly tenfold higher prevalence than the population (Singh et al. 2015).
evidence
Mucosal healing predicts hard outcomes. The Lebwohl 2013 Swedish cohort of 7,648 celiac patients with follow-up biopsy is the foundational dataset. Patients with persistent villous atrophy on follow-up biopsy had an annual lymphoma incidence of 102.4 per 100,000 vs 31.5 per 100,000 in those who healed — overall, celiac patients had a 2.81-fold higher lymphoma risk than the general population, concentrated in the non-healed group (Lebwohl et al. 2013, Ann Intern Med). The same cohort found persistent atrophy did not raise all-cause mortality (HR 1.01, 95% CI 0.86-1.19) — a finding that complicates the case for routine biopsy in asymptomatic patients (Lebwohl et al. 2013, Aliment Pharmacol Ther).
Mucosal recovery is slow and incomplete. In the Mayo cohort of 241 adults with paired biopsies, histologic recovery was 34% at 2 years and 66% at 5 years; clinical response (82%) consistently outran histologic recovery (Rubio-Tapia et al. 2010). This is the data point that breaks the assumption that "feeling better" equals "healed."
Nutrient deficiencies are common even in the contemporary (non-classical) presentation. The Mayo retrospective of 309 newly diagnosed adults found zinc deficient in 59.4%, with iron, vitamin D, copper, B12, and folate also frequently low — despite only 25% having clinical weight loss (Bledsoe et al. 2019). A Dutch cohort independently found 87% had at least one micronutrient below normal, with zinc deficient in 67%, iron stores reduced in 46%, and anemia in 32% (Wierdsma et al. 2013).
Fracture risk is real. Olmos 2008 meta-analysis confirmed a significant association between celiac and bone fractures (Olmos et al. 2008); Heikkilä 2015 quantified it — celiac at baseline raised the risk of any fracture by 30% (95% CI 1.14-1.50) and hip fracture by 69% (95% CI 1.10-2.59) in prospective studies, roughly doubling fracture rates in case-control designs (Heikkilä et al. 2015).
FDR prevalence. Singh 2015 meta-analysis pooled FDR data and found 7.5% biopsy-confirmed celiac prevalence in first-degree relatives (vs 2.3% in second-degree, vs ~1% population baseline); sisters and daughters carried the highest risk (Singh et al. 2015). Newer 2024 pooled data (34 studies, ~10,000 FDRs) gave seroprevalence 11% and biopsy-confirmed 7% — same order of magnitude.
protocol
The ACG 2023 guideline is the most current explicit protocol for adults (Rubio-Tapia et al. 2023):
- Clinical visits: multiple visits in year 1 (typically 3, 6, 12 months), then yearly or twice-yearly.
- Mandatory dietitian referral after diagnosis; subsequent visits as needed.
- tTG-IgA serology: baseline and follow-up — AGA recommends repeat at 6 and 12 months post-diagnosis, then yearly (Husby et al. 2019). Falling titres indicate adherence; rising or persistent positivity indicates ongoing gluten exposure.
- Nutrient panel at diagnosis: CBC, iron studies (ferritin), 25-OH vitamin D, B12, folate, zinc, copper. Repeat at 3-6 months if abnormal; otherwise annually (Bledsoe et al. 2019). Add thyroid (TSH), liver enzymes, calcium, phosphate per CDF protocol.
- DXA: ACG recommends a DXA at diagnosis (in adults) and repeat every 2-3 years. ESsCD limits follow-up DXAs to those with abnormal index. BSG defers initial DXA to patients >55 or with risk factors; NICE uses risk-score thresholds. Disagreement is genuine (Ludvigsson et al. 2014) (Rubio-Tapia et al. 2023).
- Follow-up duodenal biopsy: ACG suggests considering this at 2 years from GFD start in asymptomatic adults, after shared decision-making — controversial because mortality benefit is unproven (Lebwohl et al. 2013). BSG and ESsCD vary in enthusiasm; in symptomatic patients all guidelines agree biopsy is mandatory to rule out refractory disease.
- Pneumococcal vaccination due to functional hyposplenism (BSG grade C) (Ludvigsson et al. 2014).
- FDR screening: ACG and BSG recommend serologic screening (tTG-IgA + total IgA) of all FDRs. HLA-DQ2/DQ8 typing can be used as a one-time rule-out — a negative gene test essentially excludes lifetime risk; gene-positive FDRs need periodic tTG-IgA testing (every 2-3 years for asymptomatic carriers, or sooner with symptoms). Crucial caveat: relatives must remain on a gluten-containing diet during testing or serology and biopsy both fail.
contraindications
No absolute contraindications to follow-up labs. The one trap worth flagging: ~2-3% of celiac patients have selective IgA deficiency, in which IgA-based tTG falsely returns negative. Total IgA must be measured alongside the first tTG; if deficient, switch to IgG-based serology (tTG-IgG or DGP-IgG) (Husby et al. 2019) (Rubio-Tapia et al. 2023). For FDR screening, going gluten-free before testing invalidates both serology and biopsy — the relative must keep eating gluten until the workup is done (Ludvigsson et al. 2014).
misconceptions
- "Feeling better means I'm healed." Clinical response (82%) substantially outruns histologic recovery (34% at 2 years, 66% at 5 years) (Rubio-Tapia et al. 2010). Symptoms are a poor proxy for villous regrowth.
- "Normal tTG means healed mucosa." tTG sensitivity for histologic recovery is only ~50% (Husby et al. 2019) — half of patients with ongoing villous atrophy have normal serology.
- "Asymptomatic relatives don't need screening." Up to 60% of seropositive FDRs report symptoms on detailed questioning despite calling themselves asymptomatic; many have silent celiac with the same downstream risks as classical disease.
- "A gluten-free diet alone covers nutritional needs." Many commercial GF products are not fortified with iron, folate, or B vitamins to the same extent as wheat-based equivalents — annual labs catch the gap (Wierdsma et al. 2013).
- "Population screening is recommended." USPSTF 2017 issued an I-statement (insufficient evidence) for asymptomatic celiac screening in the general population — the case-finding logic only applies to relatives and to symptomatic individuals (USPSTF 2017).
audience
FDR screening applies to parents, full siblings, and biological children of the index patient — each has roughly a 1-in-10 chance of carrying celiac vs the population's 1-in-100 (Singh et al. 2015). Females (sisters, daughters) carry slightly higher risk than males. Children of celiac parents can be screened from around age 3 once they have had reliable gluten exposure for at least a year. HLA-DQ2/DQ8 typing is uniquely useful in this group: ~30-40% of the general population carries one of the alleles but is not at risk; a relative who is gene-negative can be reassured for life with one cheek swab and never needs repeat serology.
Bone-density screening is most pressing for adults over 55 and for any patient with low BMI, classical malabsorption presentation, late diagnosis, or a fragility fracture — these subgroups carry the highest risk of clinically meaningful osteoporosis (Heikkilä et al. 2015).
practicalities
The whole stack runs through primary care plus a gastroenterologist; an endoscopy unit for the optional follow-up biopsy; a dietitian (typically 2-4 visits in the first year); a radiology unit for DXA. In most insured settings annual nutrient panels and tTG cost the patient little; DXA is covered with the indication of celiac. Friction is mostly logistical (remembering yearly draws, getting FDRs to actually go) rather than financial. Time burden across a year: roughly half a day for labs and visits, plus dietitian sessions in the first year. Patients on a strict GFD report ~74% accidental gluten exposure per month from cross-contamination — annual follow-up is partly there to catch the cumulative damage from those slips.
stakes
The data signal is concentrated in three places: persistent villous atrophy roughly triples lymphoma risk vs the healed group (Lebwohl et al. 2013, Ann Intern Med); untreated nutritional deficiencies drive iron-deficiency anemia (32% in Wierdsma), peripheral neuropathy (B12), and cognitive symptoms (Wierdsma et al. 2013); low BMD drives a 30-69% excess fracture risk concentrated in hip and vertebral fractures (Heikkilä et al. 2015). Skipped FDR screening leaves the population's silent celiacs undiagnosed for decades, accumulating the same risks.
payoff
Patients with histologic recovery on follow-up biopsy have lymphoma rates roughly at the population baseline (Lebwohl et al. 2013, Ann Intern Med). BMD measurably improves after 1-2 years on a strict GFD (Rubio-Tapia et al. 2023). Iron-deficiency anemia, vitamin-D deficiency, and zinc deficiency correct over months with replacement therapy combined with mucosal recovery. FDR case-finding identifies ~7-8% of relatives who would otherwise carry undiagnosed disease for years.
failure-modes
- Stopping follow-up after the first year. The most common failure — patient feels well, stops attending. The screen for refractory celiac (the ~1-2% who don't heal despite strict adherence) gets missed; lymphoma surveillance lapses.
- Trusting serology alone. tTG is 50% sensitive for histologic recovery (Husby et al. 2019) — normal serology with persistent symptoms warrants biopsy, not reassurance.
- Relatives going gluten-free before testing. Erases both serology and biopsy findings; the workup must complete first (Ludvigsson et al. 2014).
- Missing IgA deficiency. A negative tTG-IgA in a patient with selective IgA deficiency is false-reassuring; total IgA must accompany the first serology.
- Not refreshing dietitian contact. Cross-contamination drift accumulates; a yearly dietitian check catches the slow widening of "what counts as gluten-free."
The credibility range
Optimist case. Follow-up matters and the protocol works. The Lebwohl Swedish cohort gives the clearest signal: healed-mucosa patients have lymphoma rates at population baseline; persistent-atrophy patients carry triple (Lebwohl et al. 2013, Ann Intern Med). Mucosal recovery is a modifiable endpoint — strict GFD adherence is what bridges symptoms-better to villi-healed. Routine serology and annual nutrient panels are cheap, the dietitian is high-yield in the first year, the DXA catches preventable fractures, and FDR screening identifies 7-8% of relatives with quiet disease at population-baseline cost (Singh et al. 2015). The whole protocol is closer to "standard chronic-disease care" than to "speculative add-on."
Skeptic case. The mortality data is unflattering. The same Lebwohl cohort that showed lymphoma stratification found no all-cause mortality difference between healed and unhealed patients (HR 1.01) (Lebwohl et al. 2013, Aliment Pharmacol Ther), and serious-infection rates were also similar. The follow-up biopsy is invasive, expensive, and its impact on patient-level decisions is debated — guidelines (ACG, BSG, ESsCD, NICE) genuinely disagree on whether to do it routinely. The USPSTF refused to recommend any asymptomatic screening due to insufficient evidence (USPSTF 2017). DXA timing is contested across guidelines. Annual labs in clinically well patients have no RCT backing for hard outcomes — they are pattern-recognition medicine, not trial-validated medicine.
Author's call. The protocol is real and the high-EV pieces are non-negotiable: annual tTG-IgA, baseline nutrient panel with iron/D/B12/folate/zinc, a first-year dietitian relationship, baseline DXA in adults, and serologic screening of every FDR. The lower-EV pieces — routine 2-year follow-up biopsy in asymptomatic adults, repeat DXA every 2-3 years irrespective of baseline — are reasonable but defensible to skip with good shared decision-making. The strongest single signal is the lymphoma stratification by mucosal status: it gives the follow-up biopsy a real, evidence-anchored rationale in patients whose serology or symptoms are equivocal. The FDR side is essentially uncontested — a 7.5-fold prevalence over baseline, a cheap test, and a treatable disease meets every classic screening criterion (Singh et al. 2015).
Stakeholder + incentive map
- Gastroenterology societies (ACG, AGA, BSG, ESsCD) drive guideline-level protocols; mostly aligned on the core (serology + nutrient labs + DXA + dietitian) but diverge on follow-up biopsy and DXA cadence (Rubio-Tapia et al. 2023) (Ludvigsson et al. 2014).
- USPSTF and primary-care bodies are conservative on population-level asymptomatic screening due to evidence gaps (USPSTF 2017), which sometimes leaks into under-screening of FDRs in practice.
- Celiac Disease Foundation, Beyond Celiac, national patient societies push the comprehensive panel and yearly follow-up; their advocacy pulls in favour of more rather than less monitoring.
- Endoscopy units, DXA centres, lab industries have a financial alignment with more follow-up; the skeptic case partly comes from researchers worried about over-procedure.
- Gluten-free product industry has indirect incentive: products are increasingly mainstream, but most aren't fortified to wheat-equivalent micronutrient levels — a slow driver of ongoing nutrient gaps (Wierdsma et al. 2013).
Population variability
- Sex: Sisters and daughters of index cases carry higher prevalence than brothers and sons (Singh et al. 2015). Women generally make up ~60-65% of diagnosed celiac populations.
- Age at diagnosis: Adults diagnosed later in life have higher rates of persistent villous atrophy and slower healing than children (Rubio-Tapia et al. 2010). Children typically heal histologically within 1-2 years; adults often need 2-5.
- Bone status at diagnosis: Patients over 45-55, underweight, or with classical malabsorption presentation have the highest osteoporosis prevalence at diagnosis and the steepest fracture trajectory (Heikkilä et al. 2015).
- Genetic background: HLA-DQ2 homozygotes have higher disease severity and slower healing than DQ2/DQ8 heterozygotes; the gene-positive-but-disease-negative state in FDRs is informative but not deterministic.
- Geographic variation: Diagnostic and surveillance practice differs widely — US (ACG-style aggressive nutrient panel, frequent DXA) vs UK (NICE-thresholded DXA) vs continental Europe (variable). Reader should anchor on the protocol their gastroenterologist follows; the evidence quality across them is comparable.
Knowledge gaps
- No RCT has tested follow-up biopsy vs no follow-up biopsy on patient-level outcomes; the lymphoma signal is observational (Lebwohl et al. 2013, Ann Intern Med).
- Optimal DXA cadence is undetermined; guidelines disagree because the data don't decide.
- Non-invasive biomarkers of mucosal healing (urinary gluten immunogenic peptides, fecal gluten immunogenic peptides) are emerging but not yet standard.
- The mortality null finding (HR 1.01 for persistent atrophy) is somewhat at odds with the lymphoma finding from the same cohort — competing-risk dynamics, follow-up duration, and selection into biopsy may explain the discrepancy (Lebwohl et al. 2013, Aliment Pharmacol Ther).
- Whether HLA-typing FDRs once as a screen-out tool (then dropping unscreened gene-negatives forever) is more cost-effective than recurrent tTG screening in all FDRs is unsettled.
- Long-term (10+ year) outcomes of FDRs screened and treated early (potential silent celiac) vs caught symptomatically are not well-characterised.
Scope vs brief. Brief named follow-up labs, mucosal-healing assessment, FDR screening, long-term complications, nutritional status, bone density, and family case-finding. Article covers all of these; bone density gets a section of its own inside protocol rather than a standalone, but is not dropped.
Category placement. Filed under screening (Screening & Prevention) rather than gut-digestion because the entry's substance is the surveillance + case-finding behaviour, not the gut disease itself. A separate celiac-disease entry covering pathophysiology, diagnosis, and the gluten-free diet would sit in gut-digestion and is the natural sibling for cross-link once written.
Future-link candidates. Once the following exist, wire them in:
- A primary celiac-disease entry (diagnosis, pathophysiology) — natural cross-link from this entry's audience and stakes sections.
- Gluten-free diet as a stand-alone — referenced repeatedly here as the action that makes follow-up worthwhile.
- Refractory celiac disease — flagged in out-of-scope; clinically important but specialist-territory.
- Non-celiac gluten sensitivity — clear differentiator entry the reader is likely to confuse with this.
- DXA / osteoporosis screening generally — bone-density mechanics overlap with several entries.
Rating difficulties. Longevity scored 4 (not 5): the lymphoma stratification is real and large (~3x for non-healers vs healers), but the same Lebwohl 2013 cohort found no all-cause mortality difference between healed and persistent-atrophy patients Lebwohl 2013, Aliment Pharmacol Ther. Strong on disease-specific endpoint, equivocal on lifespan — a 4 honestly reflects both. Evidence scored 4 (not 5): the core protocol has guideline consensus and large observational cohorts, but no RCT proves the follow-up biopsy or repeat-DXA cadence changes outcomes. Beauty-cumulative kept at 1 — real but secondary to nutrient correction.
Action type. Coded do rather than test because the substance is the multi-component ongoing surveillance program, not a single test. Cadence yearly represents the dominant rhythm after the heavier year-one schedule.
Audience scoping. Deliberately not narrowed by age/gender. Sister/daughter higher prevalence is mentioned in-line but not used to scope, because the entry's primary reader is the diagnosed person (any age, either gender) who needs to act on relatives.
USPSTF treatment. Included the USPSTF I-statement because primary-care doctors do invoke it to push back on FDR screening — wanted to give the reader a defence. Distinguished from population screening explicitly.
Excluded deliberately. Pediatric-specific follow-up cadence (different from adult), the dermatologic manifestation dermatitis herpetiformis, refractory celiac classification (Type I vs II), and detailed nutrient replacement dosing — each is its own entry's worth.
Celiac Follow-Up and Family Screening
In insured settings, annual tTG and nutrient panel plus baseline DXA are typically covered; out-of-pocket is well under $500/year for most patients. Uninsured costs (DXA ~$100-200, comprehensive panel ~$200-400) sit in the trivial-to-minor range.
Mucosal healing surveillance stratifies lymphoma risk substantially: persistent villous atrophy carries 3.3x the lymphoma incidence of healed mucosa (102 vs 31 per 100,000/yr) and ~2.81x the population rate (Lebwohl 2013, Ann Intern Med). FDR case-finding identifies the 7.5% of relatives carrying undiagnosed disease (Singh 2015). All-cause mortality finding from same cohort is null (Lebwohl 2013, Aliment Pharmacol Ther) — strong on disease-specific endpoints, more equivocal on lifespan.
A handful of yearly lab draws, one or two gastroenterology visits, dietitian visits in the first year, and prompting family members to screen — minor compared to the daily GFD effort itself, but more than zero.
Multiple major society guidelines (ACG 2023, BSG 2014, AGA 2019) converge on the core protocol. The Lebwohl 2013 Swedish cohort (n=7,648) and the Rubio-Tapia 2010 Mayo cohort anchor the mucosal-healing claims. Singh 2015 meta-analysis settles FDR prevalence. Some elements (follow-up biopsy cadence, DXA timing) are contested between guidelines — not a 5.
Detecting and correcting iron/B12/folate/vit-D/zinc deficiencies (87% have at least one deficiency at diagnosis per Wierdsma 2013; 59% zinc-deficient per Bledsoe 2019), plus dietitian-driven adherence in the first year, delivers clear functional improvements — less anemia-driven fatigue, fewer headaches, fewer cross-contamination flares.
Iron-deficiency anemia is present in ~32% of newly-diagnosed celiacs (Wierdsma 2013); B12 and folate deficiencies common; identifying and replacing these via the annual nutrient panel removes a real fatigue floor that GFD alone often doesn't lift fast enough.
B12 and iron correction improve cognitive symptoms; the felt 'brain fog' that many celiac patients report tracks with these deficiencies. Modest because the focus lift is downstream of nutrient correction rather than a direct mechanism.
B12/folate/iron correction lifts depressive symptoms in deficient patients; reduced uncertainty about disease status (mucosal healed, family screened) lowers chronic-illness anxiety. Real but secondary.
Correcting iron, zinc, and vitamin D deficiencies caught on follow-up labs has secondary effects on hair, nail, and skin quality over months; zinc deficient in 59% of newly diagnosed patients (Bledsoe 2019). Modest and indirect, but real.